2006 West Nile Virus Biovigilance Network

The West Nile Virus (WNV) Biovigilance Network collates data on donors (blood, tissue and hematopoietic progenitor cells) with suspected WNV infection in the United States and Canada. Data for the calendar year 2006 were collected from donor screening performed by nucleic acid testing (NAT). The data were reported to the AABB site by facilities responsible for testing virtually all donations in the United States and Canada. The reports provided here illustrate the geographic and temporal distribution of WNV infection as reflected by presumed viremic blood donors (PVDs) during the 2006 peak season.
 
This section includes a map showing locations where these PVDs have been identified; a bar graph identifying total PVDs by week collected; and a password-protected area for reports of WNV activity.

2006 U.S./Canada Map: Suspected Cases by Postal Code
WNV Presumed Viremic Donations by Week
WNV Blood Donor Data Reports  (password-protected area)

Resources:
2008 West Nile Virus Biovigilance Network
2007 West Nile Virus Biovigilance Network

Quick Links:
CDC Maps of WNV Activity
CDC FAQ on WNV

2006 U.S./Canada Map: Suspected Cases by Postal Code (updated 6/8/07)

This map shows presumed viremic donations (PVDs) by residential postal code of the donor in the United States and Canada. To be defined as a PVD, the sample must meet one of the following criteria: 1) a reactive sample that is repeatable by ID NAT, i.e., repeatable NAT reactivity using the same screening test, analogous to repeat reactivity in serology; or 2) reactivity in the Procleix assay that has a signal-to-cutoff ratio exceeding or equal to 17. PVDs are reported by facilities as they occur based on test results.

Top

2006 WNV Presumed Viremic Donations by Week (updated 6/8/07)

This bar graph identifies the total number of presumed viremic donations (PVDs) by week of donation as identified through NAT. PVDs are defined as: 1) a reactive sample that is repeatable by ID NAT, i.e., repeatable NAT reactivity using the same screening test, analogous to repeat reactivity in serology; or 2) reactivity in the Procleix assay that has a signal-to-cutoff ratio exceeding or equal to 17. PVDs are reported by facilities as they occur based on the test results.

Top

The data posted on this Web site are provided by third parties and are not verified by AABB.  Accordingly, AABB makes no guarantee or promise that the data are current, valid, or accurate. No content on this site is intended to constitute professional advice, whether medical, legal or otherwise. AABB expressly disclaims any liability or loss that may arise either directly or indirectly from relying on the information, services or other material on this site.

Reporting facilities that are HIPAA-compliant should determine what, if any, donor/patient information may be reported and should consider reporting only donors’ states of residence, not donor zip codes. AABB is not responsible for reporting facilities’ compliance with federal, state or local laws or regulations 


WNV Blood Donor Data Reports

WNV Blood Donor Data Reports (password-protected)

Support
For technical support or for more information, call +1.800.793.9376 (weekdays between 8:30 am and 5:00 pm ET).

For optimal viewing, use Microsoft Internet Explorer® 6.0 or later and set your screen resolution to 1024 x 768.

Top